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Abstract Although the biology the PLUNC (recently
renamed BPI fold, BPIF) family of secreted proteins is
poorly understood, multiple array based studies have sug-
gested that some are differentially expressed in lung dis-
eases. We have examined the expression of BPIFB1
(LPLUNC1), the prototypic two-domain containing family
member, in lungs from CF patients and in mouse models of
CF lung disease. BPIFB1 was localized in CF lung samples
along with BPIFA1, MUC5AC, CD68 and NE and directly
compared to histologically normal lung tissues and that of
bacterial pneumonia. We generated novel antibodies to
mouse BPIF proteins to conduct similar studies on ENaC
transgenic (ENaC-Tg) mice, a model for CF-like lung
disease. Small airways in CF demonstrated marked epi-
thelial staining of BPIFB1 in goblet cells but staining was
absent from alveolar regions. BPIFA1 and BPIFB1 were
not co-localised in the diseased lungs. In ENaC-Tg mice
there was strong staining of both proteins in the airways
and luminal contents. This was most marked for BPIFB1
and was noted within 2 weeks of birth. The two proteins
were present in distinct cells within epithelium. BPIFB1
was readily detected in BAL from ENaC-Tg mice but was
absent from wild-type mice. Alterations in the expression
of BPIF proteins is associated with CF lung disease in
humans and mice. It is unclear if this elevation of protein
production, which results from phenotypic alteration of the
cells within the diseased epithelium, plays a role in the
pathogenesis of the disease.Electronic supplementary material The online version of this
article (doi:10.1007/s00418-012-0990-8) contains supplementary
material, which is available to authorized users.
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Introduction
Palate lung nasal epithelium clone (PLUNC) was first
described in the nasal epithelium of the mouse embryo and
trachea/bronchi of adult mice (Weston et al. 1999). After
cloning the human and mouse PLUNC genes (Bingle and
Bingle 2000; LeClair et al. 2001), we made the key
observation that PLUNC belongs to a group of proteins that
make up a branch of a lipid transfer protein family (Bingle
and Craven 2002, 2004; Bingle et al. 2004). Due to the
complexity of this family, and conflicting gene nomen-
clature, a new nomenclature has been developed. Within
this framework all family members have been renamed
using the root symbol BPIF# for ‘‘BPI fold containing’’.
Family members that contain a single structural domain
have the designation BPIFA (so that SPLUNC1/PLUNC
becomes BPIFA1) and those containing two domains have
the designation BPIFB (so that LPLUNC1 becomes
BPIFB1) (Bingle et al. 2011a, b). This nomenclature has
been adopted throughout this paper.
The interspecies diversity and rapid evolution of BPIF
genes (Bingle et al. 2004, 2011a, b) support a role for the
proteins in host defence, although functional data are only
just starting to emerge (Gally et al. 2011; Lukinskiene et al.
2011; Shin et al. 2011; Wright et al. 2010). BPIFA1 has been
shown to have a surfactant-like function (Gakhar et al. 2010)
and also to be involved in the regulation of the amiloride-
sensitive epithelial sodium channel, ENaC (Garcia-Cabal-
lero et al. 2009), an important pathway for airway surface
liquid homeostasis critical for normal mucociliary clearance
and thus an important mechanical innate defense mechanism
of the lung (Mall 2008). BPIF proteins are predominantly
localised where innate defence is a major requirement,
namely in the nasal, tracheal and bronchial passages as well
as in major salivary glands and minor mucosal glands of the
oral cavity (Bingle and Bingle 2011). All BPIF proteins
contain signal peptides and multiple proteomic studies have
shown that members of the family are present in fluids from
these regions (Barnes et al. 2008).
BPIF proteins have been implicated in the pathophys-
iology of chronic lung diseases and in particular in cystic
fibrosis (CF). For example, proteomic analysis of nasal
epithelial cells from CF patients has demonstrated
increased levels of BPIFA1 (Roxo-Rosa et al. 2006) and
BPIFA1 and BPIFB1 are increased in sputum from
patients with CF (McCray et al. 2005) and epithelial cells
from CF patients express abundant BPIFA1 and BPIFB1
(Scheetz et al. 2004). Recent observations also have
implications for a biological role for the proteins in the
disease. As mentioned previously, BPIFA1, but not
BPIFB1, has been shown to inhibit the biochemical
activation of ENaC sodium channels by preventing pro-
teolytic processing and therefore activation of the channel
(Garcia-Caballero et al. 2009; Rollins et al. 2010). As
ENaC-mediated Na?/fluid absorption is increased in CF
airways and because this abnormality contributes to air-
way surface liquid depletion, an important mechanism in
the pathogenesis of CF lung disease (Mall 2009), it has
been hypothesized that upregulation of BPIFA1 may
counteract the basic defect and improve impaired airway
surface hydration in CF (Garcia-Caballero et al. 2009).
BPIFA1 is greatly increased in the small airways and
plugged lumens in CF (Bingle et al. 2007). Elevated
levels of BPIF proteins in CF, in the face of chronic
infection and inflammation, suggest that the protein is
rendered non-functional by the abnormal milieu present in
the airways of CF patients. Alternatively, the protein may
be upregulated as part of the innate immune defense
system in the chronically infected CF lung.
Building on our previous studies of BPIFA1 and
BPIFB1 in normal lung (Bingle et al. 2005, 2010) and
of BPIFA1 in CF tissue (Bingle et al. 2007), the present
study investigates the expression of BPIFB1 and BPIFA1
in lungs from CF patients and in bENaC-Tg mice with
CF-like lung disease (Mall et al. 2004).
Materials and methods
Immunohistochemistry
Sections from the major bronchi and peripheral lung were
cut from 15 cases of normal lung and from 10 patients with
CF who were undergoing lung transplantation. Histologi-
cally disease-free control samples were from tissue resec-
tions taken during surgery for cancer, where no tumour
tissue was seen to be present. The CF tissue was obtained
from explanted lungs. We also studied lungs from post
mortem samples from five patients who had died from
bacterial pneumonia. Tissue used in this study was
obtained with full ethical approval from the Department of
Pathology at the University of Edinburgh, UK; Papworth
Hospital, Cambridge, UK; and Sao Paulo University Hos-
pital, Sao Paulo, Brazil and used in Sheffield with local
ethical committee approval.
The slides were stained as previously described (Bingle
et al. 2005, 2007, 2010). The following antibodies were
used in this study: a rabbit polyclonal antibody against
human BPIFA1 (Campos et al. 2004) (final dilution 1:300);
rabbit polyclonal antibodies against BPIFB1 (final dilution
of 1:100 for BPIFB1A and 1:600 for BPIFB1B), (Bingle
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et al. 2010), a polyclonal antibody to human mucin 5AC
(MUC5AC, a gift from David Thornton, University of
Manchester, UK; final dilution 1:250); monoclonal anti-
bodies to CD68 and neutrophil elastase purchased from
Dako (1:400 and 1:300, respectively), and a rabbit antibody
against mouse CCSP (a gift from Barry Stripp, final dilu-
tion 1:1,000). Due to the low level of sequence similarity
that exists between mouse and human BPIFA1 (72 %) and
BPIFB1 (59 %) we developed mouse-specific antibodies to
both proteins described below. Both the BPIFA1 and
BPIFB1 antibodies were used at a final dilution of 1:750. A
standard antigen retrieval procedure using tri-sodium cit-
rate in a microwave for 8 min was used for the human and
mouse BPIFB1 antibodies as well as the MUC5AC, CD68
and CCSP antibodies. Sections were incubated with 100 %
normal serum (goat for polyclonal antibodies, horse for
monoclonal antibodies) at room temperature for 30 min
and then at 4 C overnight with the antibodies diluted as
indicated above with 100 % normal serum. Rabbit or
mouse IgGs (DAKO) were used as negative controls on
replicate slides. A Vectastain Elite ABC kit (Vector
Laboratories) containing an appropriate biotin-labelled
secondary antibody was used according to the manufac-
turer’s instructions. Peroxidase enzymatic development
was performed using a Vector NovaRed substrate kit
resulting in red staining in positive cells. Sections were
counterstained with haematoxylin, dehydrated to xylene
and mounted in DPX. Alcian blue staining of acidic mucins
was performed using a standard histological method.
Experimental animals
We used C57BL6 and C57BL6/129sv mice for examina-
tion of the normal distribution of the proteins in mice.
Animals were housed in the DePaul University and the
University of Sheffield animal care facilities and were
allowed access to food and water ad libitum. All studies
were performed with the approval of local animal care
committees. We collected tissues from mice aged
6–16 weeks with some tissues being collected following
perfusion fixation and all samples being fixed in cold 4 %
paraformaldehyde. Fixed tissues were embedded in paraf-
fin according to standard protocols.
The generation of bENaC-Tg mice (line 6608) has
been previously described (Mall et al. 2004, 2008). The
colony was maintained on a mixed genetic background
(C3H/HeN 9 C57BL/6N), and bENaC-Tg mice were
identified by PCR as described (Mall et al. 2004, 2008).
To ensure there were no strain-related differences, wild-
type (WT) littermates served as controls in all experi-
ments. Mice were housed in a specific pathogen-free
animal facility at the University of Heidelberg, Germany
and had free access to chow and water. For BAL
collection, mice were deeply anesthetized via intra-peri-
toneal injection of a combination of ketamine/xylazine
(120 and 16 mg/kg, respectively), the trachea cannulated,
and lungs lavaged with PBS. Samples were centrifuged
and the cell-free BAL fluid was stored at -80 C. For
immunohistochemical analysis, lungs that had not been
subjected to lavage were removed from mice, through a
median sternotomy. Lungs were fixed in 10 % formalin
buffered saline, paraffin embedded and sectioned. Six WT
and six bENaC-Tg mice at each of two time points (2 and
6 weeks of age) were used to generate the samples. All
experimental animal studies were approved by the Regi-
erungspra¨sidium Karlsruhe, Germany.
Western blotting
5 ll aliquots of mouse BAL from the bENaC-Tg mice and
WT littermate controls, were denatured, resolved on 12 %
SDS-PAGE gels and western blotted using specific anti-
bodies against mouse BPIFA1 and BPIFB1 (1:500 dilu-
tion). Detection was performed using ECL and X-ray film
(Amersham) following incubation with a HRP conjugated
secondary antibody (1:2,000 dilution).
Human peripheral blood neutrophils and mononuclear
(MNC) cells from normal healthy donors were isolated by
density gradient centrifugation and cultured as previously
described (Savill et al. 1989). Monocyte-derived macro-
phages (MDM) were differentiated from monocytes on
tissue culture plastic using standard protocols (Dockrell
et al. 2001). Protein samples from a given number of
purified human neutrophils and MDM were resolved on
12 % SDS-PAGE gels. 5 ll of apical secretions from pri-
mary human tracheobronchial epithelial cells differentiated
at an air liquid interface (ALI) was used as a positive
control (Bingle et al. 2007). Blots were probed with anti-
bodies to human BPIFA1 and BPIFB1 (1:500) and subse-
quently re-probed with a polyclonal antibody to human
Mcl-1 (sc-819, Santa Cruz Biotechnology Inc), a Bcl-2
family member expressed in myeloid cells (Bingle et al.
2000). This was to confirm the presence of protein in the
neutrophil and MDM lanes. Detection was performed as
above.
Results
BPIFB1 is increased in CF airways
We confirmed our previous results which showed that
expression of BPIFB1 was limited to a small number of
airway cells in histologically normal sections of large
bronchi (shown by black arrows in Fig. 1a) but was absent
from peripheral lung and alveolar macrophages.
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Expression of BPIFA1 was essentially absent from the
same regions (Fig. 1b). The use of no antibody control
slides helped to confirm the specificity of the staining
(Fig. 1c). In cases of CF, BPIFB1 staining was present in
the epithelium lining the distended and inflamed airways
(Fig. 1d, g). Again no staining was seen in the peripheral
lung tissue (Fig. 1d, e). Although both proteins are local-
ized to similar regions, i.e. conducting airways but not
alveoli (Fig. 1f), they stain different cells (Fig. 1g, h). The
BPIFB1 positive cells have the characteristics of goblet
cells whereas BPIFA1 positive cells are more basally dis-
tributed and probably represent non-ciliated cells. In
keeping with the fact that BPIF proteins are secreted, both
proteins were often localised to the luminal contents
(Fig. 1d, f), which contain both inflammatory cells and
mucoid secretions. The specificity of BPIFB1 staining in
the CF cases was confirmed using a second affinity-purified
antibody (BPIFB1A) (Bingle et al. 2010) (Supplementary
figure 1).
Goblet cell expression of BPIFB1 was confirmed
(Fig. 2a, c) by co-localisation with the goblet cell marker
protein MUC5AC (Fig. 2d), whereas these cells were
negative for BPIFA1 (Fig. 2b). Sections were stained for
neutrophil elastase to identify neutrophils and CD68 for
macrophages, (Fig. 2e, f), and this confirmed that inflam-
matory cells did not express BPIFB1 in the CF lung.
Macrophages and neutrophils in lungs from bacterial
pneumonia also did not express BPIFB1 (Fig. 2g–i).
BPIFB1 and BPIFA1 were also undetectable by western
blotting of human neutrophil and macrophage lysates
(Supplementary figure 2).
As patients with CF have significant airway remodelling
associated with repeated chronic bacterial infections, it is
unclear what is responsible for the elevated production of
Fig. 1 Increased BPIFB1 and BPIFA1 in CF lung. Immunohisto-
chemistry for BPIFB1 (a, d, e, g) and BPIFA1 (b, f, h) was performed
as described in ‘‘Materials and methods’’. Sections show staining in
samples of normal large airway (a–c) and in sections from patients
with cystic fibrosis (d–i). Sections c and i are controls (no primary
antibody). The black arrows in panel a indicated BPIFB1 positive
cells in the normal airway. Scale bars are present on each individual
panel
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BPIFB1 in the disease. The severity of the lung disease in
the patient samples available also makes it difficult to study
differential expression of the proteins in the early stage of
disease. To address this issue, we studied the localisation of
BPIF proteins in the lungs of mice with a CF-like lung
disease.
Fig. 2 BPIFB1 is predominantly expressed in a goblet cell popula-
tion in CF airways and is absent from neutrophils and macrophages.
Immunohistochemistry for BPIFB1 (a, c, g), BPIFA1 (b), MUC5AC
(d) NE (e, i) and CD68 (f, h) was performed as described in
‘‘Materials and methods’’ using sections from patients with cystic
fibrosis (a–f) or from bacterial pneumonia (g–i). Scale bars are
present on each individual panel
Histochem Cell Biol (2012) 138:749–758 753
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BPIFB1 and BPIFA1 are differentially expressed
in the respiratory tract of mice
We initially localised BPIFB1 and BPIFA1 in lung
sections from WT mice using novel species-specific
antibodies. BPIFA1 was strongly expressed in the
non-ciliated epithelial cells of the trachea (Fig. 3a, and
Supplementary figure 3C, D) but was not co-localised
with acid mucins as shown by distinct Alcian blue staining
in the mucous cells of the tracheal submucosal glands
(SMG) (Supplementary figure 3A, B). BPIFB1 staining
was seen in a much smaller population of non-ciliated
epithelial cells than BPIFA1 (shown by black arrows in
Fig. 3b). These cells may represent the rare goblet cells
seen in normal mouse trachea. Airway SMGs were neg-
ative for BPIFB1 (not shown). In more distal sections of
the airways, BPIFA1 staining was more prominent than
that of BPIFB1 (Fig. 3c, d). As airways became smaller,
and within the peripheral lung, staining of both proteins
was lost (Fig. 3e, f), whereas the Clara cell marker,
SCGB1A1, was seen throughout the smaller airways
(Fig. 3f, inset).
Expression of BPIFB1 and BPIFA1 is increased
in a mouse model of CF lung disease
Having established that mouse BPIF proteins had similar
distribution patterns to that seen in humans, we determined
their expression in a well-established murine CF model, the
ENaC-Tg mouse which phenocopies the airway surface
liquid depletion and impaired mucus clearance seen in CF
(Mall et al. 2004; Zhou et al. 2011).
Lungs from 2-week-old WT mice were negative for
BPIFB1 (Fig. 4a) whereas SCGB1A1 (which drives
expression of the transgene) stained the surface airway
epithelium (Fig. 4b). Neither BPIFB1 nor BPIFA1 were
seen in 6-week-old WT lungs (Fig. 4e, f). In marked con-
trast there was significant BPIFB1 staining in lungs from
2- and 6-week-old ENaC-Tg mice (Fig. 4c, g, i, j) with the
protein being seen in both the epithelial cells lining the
airways and in the luminal contents. Strong staining of
BPIFA1 was also seen in some of the ENaC-Tg lungs
(compare Fig. 4k, l with d, h). Close examination of the
sections revealed that BPIFA1 stained a greater number of
cells than did BPIFB1 (Fig. 4j, l) but it is not clear from our
data if the proteins co-localise.
BAL from 6-week-old transgenic mice contains read-
ily detectable BPIFB1 whereas samples from age-mat-
ched wild-type littermate controls do not (Fig. 5). In
contrast, BPIFA1 was present in similar amounts in both
transgenic and wild-type BAL fluid samples. Importantly,
neither protein exhibited any evidence of significant
proteolysis.
Discussion
Although the prototypic two-domain BPIF protein,
BPIFB1, has been identified in multiple proteomic and
genomic studies (Barnes et al. 2008), information on the
tissue localisation of the protein and its role in lung biology
and disease is very limited (Bingle et al. 2010). As BPIF
proteins have been increasingly implicated in the patho-
genesis of CF (Garcia-Caballero et al. 2009; Roxo-Rosa
et al. 2006; McCray et al. 2005; Bingle et al. 2007) we
undertook to study BPIFB1 in both diseased human tissue
and in an established mouse model of CF.
Strikingly, BPIFB1 is greatly increased in the chroni-
cally inflamed lungs of patients with CF, a condition that is
characterised by mucous cell hyperplasia (Burgel et al.
2007; Henke et al. 2007). Coupled with repeated cycles of
chronic infection, CF lung disease results in thickened
mucoid secretions that contain multiple inflammatory cells
and harbour a host of pathogens. Our data show that in CF,
BPIFB1 is produced in goblet cells in regions of the lung
that co-express MUC5AC and the protein is part of the
viscous complex that occludes the airways. BPIFB1 (and
BPIFA1) has previously been shown to be associated with
the mucus-containing fraction of BAL lavage fluid and
sputum (Kesimer et al. 2009) and it seems likely that it
makes up part of the protective shield that overlies the
airway epithelium. Although BPIFA1 has been implicated
in regulating ENaC activity and airway surface liquid to
counteract the CF defect (Garcia-Caballero et al. 2009;
Rollins et al. 2010), the function of BPIFB1 in this location
remains unknown.
Despite the significant levels of BPIFB1 staining seen in
the airway epithelium in CF, there was no staining in the
peripheral lung. We have previously reported increased
BPIFA1 protein in airway epithelial cells in CF (Bingle
et al. 2007) but, similar to the situation seen with BPIFB1,
it was not detected in the peripheral lung. Importantly,
BPIFB1 is not co-localised with BPIFA1 in CF. This rep-
licates the situation we have described in non-diseased lung
tissue (Bingle et al. 2005, 2010) and shows that the
mechanisms which govern the spatial regulation of these
two genes is retained in CF. Although the mechanisms that
govern the expression of BPIF proteins have not been
elucidated, we and others have shown that both proteins are
significantly expressed in tracheobronchial epithelial cells
differentiated at the ALI and that their expression is
modulated by the differentiation status of the cultures
(Bingle et al. 2007, 2010; Ross et al. 2007). We have not
shown that BPIFB1 is a direct transcriptional target of pro-
inflammatory mediators, including IL-1b, TNFa and bac-
terial LPS (data not shown). A proteomic study (Candiano
et al. 2007) also showed no significant increase of BPIFB1
following cytokine treatment of ALI cells. Our results
754 Histochem Cell Biol (2012) 138:749–758
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suggest that it is the phenotypic alteration in the epithe-
lium, potentially induced by airway surface liquid deple-
tion in CF airways that leads to the increase in both
proteins and is not, therefore, the response of a single
epithelial cell type in the diseased lung.
BPIFB1 is not produced by inflammatory cells present
in the luminal contents of the diseased lung, or by those
resident within the lung tissues. Due to the nature of the
lung tissue in CF, it is difficult to differentiate between
staining of BPIF proteins in the mucus surrounding the
inflammatory cells or within the cells themselves. In
addition BPIFA1 has also been reported to be present in
neutrophil granules (Bartlett et al. 2008). We addressed
these issues using cases of bacterial pneumonia where
significant numbers of neutrophils and macrophages were
seen but where no BPIFB1 staining was noted. We also
failed to detect BPIFB1 and BPIFA1 in MDMs and
peripheral blood neutrophils by western blotting. These
data, along with lack of identification of either protein in
multiple neutrophil and macrophage proteomic datasets
(Bewley et al. 2011; Kraft-Terry and Gendelman 2011;
Lietze´n et al. 2011), strongly support our view that BPIF
proteins are not produced at significant levels by cells of
the myeloid lineage, but that epithelial cells secrete both
proteins into the lumen.
This paper is the first to show localisation of either
BPIFA1 or BPIFB1 in the mouse lung. Bpifa1 was origi-
nally identified in developing nasal passages and the upper
respiratory tract of adult mice (Weston et al. 1999). Our
data confirm that the upper airway is a major site of protein
production. The staining appears to be in a non-ciliated cell
population, even though the protein is clearly associated
with the ciliated cell surface in both locations. Expression
of BPIFA1 does not always co-localise with the Clara cell
marker SCGB1A1 (CCSP) in the airway, as expression of
BPIFA1 is lost in the more distal Clara cells, which retain
very strong expression of SCGB1A1. Further evidence that
the protein is produced in non-ciliated cells comes from the
Fig. 3 BPIFA1 and BPIFB1 do
not co-localise in the adult
mouse respiratory tract.
Immunohistochemistry was
performed as described in
‘‘Materials and methods’’ using
antibodies specific for murine
BPIFA1 (a, c, e) and BPIFB1
(b, d, f). Sections show serial
samples of the trachea (a, b),
large airways (c, d) and smaller
airways and peripheral lung
(e, f). The inset figure in
f represents staining of a further
section with the Clara cell
marker, SCGB1A1 (CCSP). The
black arrows identify the rare
BPIFB1 positive cells in the
normal mouse trachea. Scale
bars are present on each
individual panel
Histochem Cell Biol (2012) 138:749–758 755
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observation that strong staining of BPIFA1 is still seen in
mice lacking ciliated cells due to the deletion of foxj1 (data
not shown). This cellular localisation is consistent with that
seen for the human proteins (Bingle et al. 2005, 2010).
BPIFB1 is present in what appears to be goblet cells
within the large, conducting airways. Staining in the tra-
chea and upper airways for BPIFB1 is therefore more
limited than for BPIFA1 as there are few goblet cells
present in the airways of healthy mice (Livraghi et al.
2009). Goblet cells in other locations, including for
example the GI tract and the conjunctiva, do not stain for
BPIFB1 (data not shown). One of the important findings
from our study is that in the normal mouse lung expression
of BPIFB1 is very limited. This is consistent with the very
limited reports of BPIFB1 being found in proteomic data-
sets of mouse BAL (Guo et al. 2005; Gharib et al. 2010) as
well as our observations that limited detectable protein is
present in BAL from normal mice (Fig. 5). The lack of
staining of either protein in the normal mouse lung
parenchyma also mirrors the situation in humans (Bingle
et al. 2005, 2010).
The data from the lungs of bENaC-Tg mice suggest
that it is the airway surface lining depletion-induced
airway disease and epithelial remodeling, rather than the
loss of CFTR function and/or chronic infection per se,
that is responsible for the differential expression of
BPIFB1 in the CF lung. As expected from previous
studies (Wilke et al. 2011), Cftrtm1Unc mice showed no
Fig. 4 BPIFB1 and BPIFA1 are increased in the occluded airways of
scgb1a1-ENaC transgenic mice. Immunohistochemistry was per-
formed as described in ‘‘Materials and methods’’ using antibodies
specific for murine BPIFB1 (a, c, e, g, i, j) and BPIFA1 (d, f, h, k, l)
and SCGB1A1 (b). Sections show serial samples of lungs from
2 week old wild type mice (a, b), 2 week old transgenic mice
(c, d) 6 week old wild type mice (e–f) and 6 week old transgenic
mice (g–l). Scale bars are present on each individual panel
Fig. 5 BPIFB1 is significantly increased in the BAL fluid of
Scgb1a1-ENaC transgenic mice. Replicate SDS-PAGE gels of BAL
fluid samples from three wild type and three transgenic mice (both at
6 weeks of age) were generated as outlined in ‘‘Materials and
methods’’. The resultant blots were subjected to western blotting and
detected with specific antibodies against mouse BPIFB1 and BPIFA1
as described. The position of the molecular mass markers are
indicated by the black arrows
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evidence of CF-like lung disease, and perhaps not
unexpectedly, analysis of lung tissues revealed that there
were no readily detectable differences in the staining
intensity or localization of BPIF proteins (data not
shown). In contrast to this, and again mirroring the data
seen in human CF, we found significant BPIFB1 staining
associated with CF-like mucus obstruction, goblet cell
metaplasia and inflammation in the airways of the
bENaC-Tg mice. In this model, overexpression of bENaC
in the airway epithelium causes increased airway Na?
absorption that results in airway surface liquid depletion.
This in turn causes a reduction in mucus transport due to
increased viscosity and to the development of a sponta-
neous CF-like lung disease with the characteristic airway
mucus obstruction and chronic airway inflammation (Mall
et al. 2004, 2008; Zhou et al. 2011). Unlike the situation
seen in human CF, this model is not associated with
chronic bacterial infections and, therefore, should prove
to be useful in further understanding the function of BPIF
proteins in the pathogenesis of CF lung disease. At this
time it is unclear why the induced expression of BPIFA1
in this model is not seen in all bENaC-Tg mice, but our
assumption is that animals that express more BPIFA1 are
likely to have a lesser number of clara cells than those
with lower expression. This requires more quantitative
analysis.
In summary, we have shown a significant increase in
BPIFB1 in the airways of patients with CF as well as in a
murine model of the disease. It is unclear if the increased
production of BPIF proteins in CF influences the devel-
opment of lung disease but it seems likely that the
increased production of these putative host defence pro-
teins will be a response to the epithelial remodeling that
accompanies this condition. The nature of our studies does
not allow us to determine if increased BPIF production is
associated with disease severity but as the proteins are
readily detectable in BAL fluid, the development of
quantitative assays will enable its role as a potential bio-
marker for disease severity to be studied.
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